Research ExplorerPublicationsImmunotherapy in Advanced Prostate Cancer-Light at the End o...

Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel?

Standard

Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel? / von Amsberg, Gunhild; Alsdorf, Winfried; Karagiannis, Panagiotis; Coym, Anja; Kaune, Moritz; Werner, Stefan; Graefen, Markus; Bokemeyer, Carsten; Merkens, Lina; Dyshlovoy, Sergey A.

In: INT J MOL SCI, Vol. 23, No. 5, 2569, 25.02.2022.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

von Amsberg, G, Alsdorf, W, Karagiannis, P, Coym, A, Kaune, M, Werner, S, Graefen, M, Bokemeyer, C, Merkens, L & Dyshlovoy, SA 2022, 'Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel?', INT J MOL SCI, vol. 23, no. 5, 2569. https://doi.org/10.3390/ijms23052569

APA

von Amsberg, G., Alsdorf, W., Karagiannis, P., Coym, A., Kaune, M., Werner, S., Graefen, M., Bokemeyer, C., Merkens, L., & Dyshlovoy, S. A. (2022). Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel? INT J MOL SCI, 23(5), [2569]. https://doi.org/10.3390/ijms23052569

Vancouver

von Amsberg G, Alsdorf W, Karagiannis P, Coym A, Kaune M, Werner S et al. Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel? INT J MOL SCI. 2022 Feb 25;23(5). 2569. https://doi.org/10.3390/ijms23052569

Bibtex

@article{193ef71946214cc0a4fb7f6fd7100b31,
title = "Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel?",
abstract = "Immunotherapeutic treatment approaches are now an integral part of the treatment of many solid tumors. However, attempts to integrate immunotherapy into the treatment of prostate cancer have been disappointing so far. This is due to a highly immunosuppressive, {"}cold{"} tumor microenvironment, which is characterized, for example, by the absence of cytotoxic T cells, an increased number of myeloid-derived suppressor cells or regulatory T cells, a decreased number of tumor antigens, or a defect in antigen presentation. The consequence is a reduced efficacy of many established immunotherapeutic treatments such as checkpoint inhibitors. However, a growing understanding of the underlying mechanisms of tumor-immune system interactions raises hopes that immunotherapeutic strategies can be optimized in the future. The aim of this review is to provide an overview of the current status and future directions of immunotherapy development in prostate cancer. Background information on immune response and tumor microenvironment will help to better understand current therapeutic strategies under preclinical and clinical development.",
author = "{von Amsberg}, Gunhild and Winfried Alsdorf and Panagiotis Karagiannis and Anja Coym and Moritz Kaune and Stefan Werner and Markus Graefen and Carsten Bokemeyer and Lina Merkens and Dyshlovoy, {Sergey A}",
year = "2022",
month = feb,
day = "25",
doi = "10.3390/ijms23052569",
language = "English",
volume = "23",
journal = "INT J MOL SCI",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "5",

}

RIS

TY - JOUR

T1 - Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel?

AU - von Amsberg, Gunhild

AU - Alsdorf, Winfried

AU - Karagiannis, Panagiotis

AU - Coym, Anja

AU - Kaune, Moritz

AU - Werner, Stefan

AU - Graefen, Markus

AU - Bokemeyer, Carsten

AU - Merkens, Lina

AU - Dyshlovoy, Sergey A

PY - 2022/2/25

Y1 - 2022/2/25

N2 - Immunotherapeutic treatment approaches are now an integral part of the treatment of many solid tumors. However, attempts to integrate immunotherapy into the treatment of prostate cancer have been disappointing so far. This is due to a highly immunosuppressive, "cold" tumor microenvironment, which is characterized, for example, by the absence of cytotoxic T cells, an increased number of myeloid-derived suppressor cells or regulatory T cells, a decreased number of tumor antigens, or a defect in antigen presentation. The consequence is a reduced efficacy of many established immunotherapeutic treatments such as checkpoint inhibitors. However, a growing understanding of the underlying mechanisms of tumor-immune system interactions raises hopes that immunotherapeutic strategies can be optimized in the future. The aim of this review is to provide an overview of the current status and future directions of immunotherapy development in prostate cancer. Background information on immune response and tumor microenvironment will help to better understand current therapeutic strategies under preclinical and clinical development.

AB - Immunotherapeutic treatment approaches are now an integral part of the treatment of many solid tumors. However, attempts to integrate immunotherapy into the treatment of prostate cancer have been disappointing so far. This is due to a highly immunosuppressive, "cold" tumor microenvironment, which is characterized, for example, by the absence of cytotoxic T cells, an increased number of myeloid-derived suppressor cells or regulatory T cells, a decreased number of tumor antigens, or a defect in antigen presentation. The consequence is a reduced efficacy of many established immunotherapeutic treatments such as checkpoint inhibitors. However, a growing understanding of the underlying mechanisms of tumor-immune system interactions raises hopes that immunotherapeutic strategies can be optimized in the future. The aim of this review is to provide an overview of the current status and future directions of immunotherapy development in prostate cancer. Background information on immune response and tumor microenvironment will help to better understand current therapeutic strategies under preclinical and clinical development.

U2 - 10.3390/ijms23052569

DO - 10.3390/ijms23052569

M3 - SCORING: Review article

C2 - 35269712

VL - 23

JO - INT J MOL SCI

JF - INT J MOL SCI

SN - 1661-6596

IS - 5

M1 - 2569

ER -